Onconeural antibody-associated cerebellar ataxia: An analysis
BACKGROUND: Cohort-based studies on onconeural antibody-associated cerebellar ataxia (CA) investigating the immunological and radiological spectrum as well as functional outcomes are limited. OBJECTIVE: To study the clinical, radiological, and immunological spectrum, as well as the treatment profile...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2024-05-01
|
| Series: | Annals of Movement Disorders |
| Subjects: | |
| Online Access: | https://doi.org/10.4103/aomd.aomd_24_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850074382765916160 |
|---|---|
| author | Rohan Mahale Sandeep M Anitha Mahadevan Nitish Kamble Vikram Holla Pramod K. Pal Ravi Yadav |
| author_facet | Rohan Mahale Sandeep M Anitha Mahadevan Nitish Kamble Vikram Holla Pramod K. Pal Ravi Yadav |
| author_sort | Rohan Mahale |
| collection | DOAJ |
| description | BACKGROUND: Cohort-based studies on onconeural antibody-associated cerebellar ataxia (CA) investigating the immunological and radiological spectrum as well as functional outcomes are limited. OBJECTIVE: To study the clinical, radiological, and immunological spectrum, as well as the treatment profile and outcomes, of onconeural antibody-associated CA. METHODS: A retrospective descriptive analysis was performed for a cohort of patients who presented with CA and had positive onconeural antibodies in serum. The clinical, radiological, and immunological spectrum and the treatment profile and outcomes of the patients were analyzed. RESULTS: Thirty-two patients were diagnosed with onconeural antibody-associated CA and were selected for our analysis. Eighteen patients (56%) had anti-Yo, seven (22%) had anti-Zic4, four (12.5%) had anti-CV2/CRMP5, two (6.25%) had anti-Hu, and one had anti-PCA-2 antibodies. The median duration of illness was 4 months (interquartile range (IQR): 3–6 months). Twenty-eight patients had pancerebellar syndrome. The mean score of the Scale for the Assessment and Rating of Ataxia (SARA) was 23.9 ± 5.2 (range: 16–34; median: 26). Bilateral cerebellar atrophy was observed in 24 patients (75%). Four patients with anti-Yo antibodies had breast lesions on screening at the time of admission. Two patients with anti-Yo antibodies had carcinoma ovary at 1-year follow-up. The median modified Rankin scale (mRS) score at admission was 4. Twelve patients underwent a 6-month follow-up (37%) and eight had a 1-year follow-up. Favorable outcomes (mRS scores ≤ 2) were observed in five patients (42%), whereas poor outcomes were observed in seven patients (58%). CONCLUSION: CA was most commonly caused by anti-Yo antibodies, followed by anti-Zic4 antibodies. Patients with anti-Zic4 antibodies had the lowest mean SARA score and the most favorable functional outcome. Patients with anti-Yo had poor functional outcomes with immunotherapy. |
| format | Article |
| id | doaj-art-40de762c3859481385c6c91c0a5a28f0 |
| institution | DOAJ |
| issn | 2590-3446 2590-3454 |
| language | English |
| publishDate | 2024-05-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Annals of Movement Disorders |
| spelling | doaj-art-40de762c3859481385c6c91c0a5a28f02025-08-20T02:46:36ZengWolters Kluwer Medknow PublicationsAnnals of Movement Disorders2590-34462590-34542024-05-017210210710.4103/aomd.aomd_24_24Onconeural antibody-associated cerebellar ataxia: An analysisRohan MahaleSandeep MAnitha MahadevanNitish KambleVikram HollaPramod K. PalRavi YadavBACKGROUND: Cohort-based studies on onconeural antibody-associated cerebellar ataxia (CA) investigating the immunological and radiological spectrum as well as functional outcomes are limited. OBJECTIVE: To study the clinical, radiological, and immunological spectrum, as well as the treatment profile and outcomes, of onconeural antibody-associated CA. METHODS: A retrospective descriptive analysis was performed for a cohort of patients who presented with CA and had positive onconeural antibodies in serum. The clinical, radiological, and immunological spectrum and the treatment profile and outcomes of the patients were analyzed. RESULTS: Thirty-two patients were diagnosed with onconeural antibody-associated CA and were selected for our analysis. Eighteen patients (56%) had anti-Yo, seven (22%) had anti-Zic4, four (12.5%) had anti-CV2/CRMP5, two (6.25%) had anti-Hu, and one had anti-PCA-2 antibodies. The median duration of illness was 4 months (interquartile range (IQR): 3–6 months). Twenty-eight patients had pancerebellar syndrome. The mean score of the Scale for the Assessment and Rating of Ataxia (SARA) was 23.9 ± 5.2 (range: 16–34; median: 26). Bilateral cerebellar atrophy was observed in 24 patients (75%). Four patients with anti-Yo antibodies had breast lesions on screening at the time of admission. Two patients with anti-Yo antibodies had carcinoma ovary at 1-year follow-up. The median modified Rankin scale (mRS) score at admission was 4. Twelve patients underwent a 6-month follow-up (37%) and eight had a 1-year follow-up. Favorable outcomes (mRS scores ≤ 2) were observed in five patients (42%), whereas poor outcomes were observed in seven patients (58%). CONCLUSION: CA was most commonly caused by anti-Yo antibodies, followed by anti-Zic4 antibodies. Patients with anti-Zic4 antibodies had the lowest mean SARA score and the most favorable functional outcome. Patients with anti-Yo had poor functional outcomes with immunotherapy.https://doi.org/10.4103/aomd.aomd_24_24cerebellar ataxiacerebellar atrophyimmune-mediated ataxiaimmunotherapyneoplasmonconeural antibody |
| spellingShingle | Rohan Mahale Sandeep M Anitha Mahadevan Nitish Kamble Vikram Holla Pramod K. Pal Ravi Yadav Onconeural antibody-associated cerebellar ataxia: An analysis Annals of Movement Disorders cerebellar ataxia cerebellar atrophy immune-mediated ataxia immunotherapy neoplasm onconeural antibody |
| title | Onconeural antibody-associated cerebellar ataxia: An analysis |
| title_full | Onconeural antibody-associated cerebellar ataxia: An analysis |
| title_fullStr | Onconeural antibody-associated cerebellar ataxia: An analysis |
| title_full_unstemmed | Onconeural antibody-associated cerebellar ataxia: An analysis |
| title_short | Onconeural antibody-associated cerebellar ataxia: An analysis |
| title_sort | onconeural antibody associated cerebellar ataxia an analysis |
| topic | cerebellar ataxia cerebellar atrophy immune-mediated ataxia immunotherapy neoplasm onconeural antibody |
| url | https://doi.org/10.4103/aomd.aomd_24_24 |
| work_keys_str_mv | AT rohanmahale onconeuralantibodyassociatedcerebellarataxiaananalysis AT sandeepm onconeuralantibodyassociatedcerebellarataxiaananalysis AT anithamahadevan onconeuralantibodyassociatedcerebellarataxiaananalysis AT nitishkamble onconeuralantibodyassociatedcerebellarataxiaananalysis AT vikramholla onconeuralantibodyassociatedcerebellarataxiaananalysis AT pramodkpal onconeuralantibodyassociatedcerebellarataxiaananalysis AT raviyadav onconeuralantibodyassociatedcerebellarataxiaananalysis |